Jean-Marie Michot, MD, Shares Olympia-3 Insights on Odronextamab Plus Chemotherapy in DLBCL

Jean-Marie Michot, MD, of the Gustave Roussy Cancer Center, discussed results of the Olympia-3 study presented at the 67th American Society of Hematology Annual Meeting & Exposition. The phase 3 trial evaluated odronextamab in combination with chemotherapy in patients with previously untreated diffuse large B-cell lymphoma (DLBCL).

“We know that odronextamab could be potentially superior to rituximab, as odronextamab demonstrated previously in the context of relapsed or refractory diffuse large B-cell lymphoma, accompanying efficacy,” Dr. Michot said. “We know that from a rational and scientific point of view, odronextamab and rituximab could share the same potential tumor targets on CD20.”

Dr. Michot and colleagues evaluated two dose levels of odronextamab: 180 mg and 160 mg. Step-up dosing was implemented to improve tolerability, and the researchers did not observe any new toxicities with the combination. Cytokine release syndrome occurred in 54% of patients, which is expected with bispecific antibodies, Dr. Michot noted. As for efficacy, the complete remission rate was 100% at the 160 mg dose level.

Finally, Dr. Michot discussed key biomarkers that offer insight into which patients may benefit most from therapy.

“We observed the complete depletion of B cells after the first dose of odronextamab, meaning that the treatment is associated with a profound effect on B cells. We have observed that the B cell count is 0 during treatment, meaning that the activity of the treatment is confirmed by this biomarker,” Dr. Michot shared. “The other biomarker is T cell margination. We observed T cell margination after the first dose of the treatment with a dip of the T cells. It was important to confirm that margination of T cells is also associated with the efficacy of the treatment, as we previously observed with other studies.”